Healthy
Conditions
Brief summary
The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.
Interventions
DRUGBI 1026706
DRUGPlacebo
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Signed informed consent consistent with ICH-Good Clinical Practice (GCP) guidelines and local legislation prior to participation in the trial. * Healthy volunteers of both sex between 18 and 65 years (inclusive) of age, on the day of subject's signature of informed consent. * Healthy subjects as assessed by the investigator, based on a screening examination including medical history, physical examination, vital signs (blood pressure, pulse rate, body temperature), 12-lead ECG, lung function and clinical laboratory results. * Forced expiratory volume (FEV1) of \>80% and FEV1/Forced vital capacity(fFVC) of \>70% of the predicted normal value at screening * Current smokers with a smoking history of at least 1 pack year and with at least 1 cigarette per day in the previous year * BMI (Body mass index) range: \>18.5 and \< 29.9kg/m2. * Negative urine drug screening. * Negative breath alcohol test. * Negative skin prick test (performed within the 12 months prior to study start or at study start) * Females NOT of childbearing potential are defined as: Women who are postmenopausal (12 months with no menses without an alternative medical cause; in questionable cases a blood sample with simultaneous levels of FSH above 40 U/L and estradiol below 30 ng/L is confirmatory) or who are permanently sterilized (defined as hysterectomy, bilateral oophorectomy or bilateral salpingectomy). * Further inclusion criteria apply
Exclusion criteria
* History of any relevant lung disease (i.e. Chronic Obstructive Pulmonary Disease (COPD), asthma, chronic bronchitis, pulmonary fibrosis, pulmonary alveolar proteinosis (PAP), pneumocystis infection, active tuberculosis, silicosis or any other lung surfactant overproduction syndromes). * Subjects with clinically relevant abnormal hematology, blood chemistry, or urinalysis at the screening visit * Any finding of the medical examination (including blood pressure, pulse rate, body temperature and ECG) deviating from normal and of clinical relevance. * Subjects with a history of any clinically significant cardiovascular, metabolic, renal (including renal stones), hepatic, gastrointestinal, hematological, dermatological, venereal, neurological, psychiatric or other major disorders. * Subjects with a malignancy for which the subject has undergone resection, radiation therapy or chemotherapy within the last five years. Subjects with treated basal cell carcinoma or fully cured squamous cell carcinoma are allowed to participate. * Subjects with previous surgery of the gastro-intestinal tract likely to affect drug absorption. * History of relevant orthostatic hypotension, fainting spells or blackouts. * Subjects with clinically relevant infection or known ongoing clinically relevant inflammatory process. * History of relevant allergy/hypersensitivity including allergy to drug or its excipients or medications in line with bronchoscopy (bronchodilators, sedatives and local anesthetics). * Subjects with a marked baseline prolongation of QT/QTcB interval (such as repeated demonstration of a QTcB interval \>450 ms), or any other relevant ECG finding at screening visit (Visit 1) according to the investigator. * Neutrophil blood count indicative of immunosuppression according to the investigator at screening visit (Visit 1). * Subjects with previous surgeries that may have left ferromagnetic material in the body, ferromagnetic implants or pacemakers. * Participation in another study with any investigational product within 2 months prior to screening or if screening occurs within 6 half-lives of intake of another investigational drug (whichever is greater). * Male subjects who do not agree to minimize the risk of female partners becoming pregnant from the first dosing day until 3 months after the trial medication treatment has finished. * Subjects who are committed to an institution by way of official or juridical order will not be enrolled in the trial. * Receipt of live (attenuated) vaccine within the 4 weeks prior to screening or during the trial. * Subject is assessed as unsuitable for inclusion by the investigator; for instance, because he is not considered able to understand and comply with study requirements or has a condition that would not allow safe participation in the study. * For female subjects: * Positive pregnancy test at screening Visit 1, pregnancy or plans to become pregnant within 30 days after study completion * Lactation * Further
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid After 24 Hours of the Segmental Lipopolysaccharide (LPS) Challenge | Day 29 | Total cell count of neutrophils in Bronchoalveolar Lavage (BAL) fluid after 24 hours of the segmental Lipopolysaccharide (LPS) challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the Least Square (LS) means obtained by fitting an Analysis of variance (ANOVA) model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total Cell Count of Eosinophil in BAL Fluid After 24 Hours of the Segmental LPS Challenge | Day 29 | Total cell count of eosinophil in BAL fluid after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. |
| Differential Cell Count of Eosinophil in BAL Fluid 24 h After Segmental LPS Challenge. | Day 29 | Differential cell count of eosinophil in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. |
| Total Cell Count of Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge | Day 29 | Total cell count of monocyte in BAL fluid after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Monocyte cell count is the only cell count which was assessed by means of flow cytometry. |
| Differential Cell Count of Monocyte in BAL Fluid 24 h After Segmental LPS Challenge. | Day 29 | Differential cell count of monocyte (determined by flow cytometry) in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Monocyte cell count is the only cell count which was assessed by means of flow cytometry. |
| Differential Cell Count of Neutrophils in BAL Fluid 24 h After Segmental LPS Challenge. | Day 29 | Differential cell count of neutrophils in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. |
| Differential Cell Count of Macrophage+Monocyte in BAL Fluid 24 h After Segmental LPS Challenge. | Day 29 | Differential cell count of macrophage+monocyte in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Cytospin microscopy method cannot clearly differentiate between macrophages and monocytes, the total and differential cell count of macrophages and monocytes are presented together. |
| Total Cell Count of Lymphocyte in BAL After 24 Hours of the Segmental LPS Challenge | Day 29 | Total cell count of lymphocyte after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. |
| Differential Cell Count of Lymphocyte in BAL Fluid 24 h After Segmental LPS Challenge. | Day 29 | Differential cell count of lymphocyte in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. |
| Total Cell Count of Macrophage+Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge | Day 29 | Total cell count of macrophage+monocyte BAL fluid after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Cytospin microscopy method cannot clearly differentiate between macrophages and monocytes, the total and differential cell count of macrophages and monocytes are presented together. |
Countries
Germany
Participant flow
Recruitment details
This was a randomised, placebo-controlled, double-blind, parallel-group study in a single trial center. In this study 57 healthy smoking subjects were entered and randomized. Subjects were allowed to rescreened twice based on investigator´s judgment with new informed consent & unique study subject number.
Pre-assignment details
All subjects (Subjs) were screened for eligibility to participate in trial. Subjs attended specialist site to ensure that they (the Subjs) met all implemented inclusion/exclusion criteria. Subjs were not to be randomised to trial drug if any of specific entry criteria was violated.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Subjects were orally treated with matching placebo as film-coated tablets twice daily in the morning and evening from beginning on Day 1 (Visit 2) until Day 28. | 28 |
| BI 1026706 Subjects were orally treated with BI 1026706 as film-coated tablets 100 mg twice daily in the morning and evening from beginning on Day 1 (Visit 2) until Day 28. | 29 |
| Total | 57 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 3 | 7 |
Baseline characteristics
| Characteristic | Placebo | Total | BI 1026706 |
|---|---|---|---|
| Age, Continuous | 32.4 Years STANDARD_DEVIATION 8.4 | 31.6 Years STANDARD_DEVIATION 7 | 30.8 Years STANDARD_DEVIATION 5.4 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 28 Participants | 57 Participants | 29 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 28 Participants | 57 Participants | 29 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 28 Participants | 57 Participants | 29 Participants |
| Total neutrophil count | 2.79 cells*10^3/mL STANDARD_DEVIATION 2.46 | 3.07 cells*10^3/mL STANDARD_DEVIATION 3.34 | 3.39 cells*10^3/mL STANDARD_DEVIATION 4.13 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 28 | 0 / 29 |
| other Total, other adverse events | 21 / 28 | 18 / 29 |
| serious Total, serious adverse events | 1 / 28 | 1 / 29 |
Outcome results
Primary
Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid After 24 Hours of the Segmental Lipopolysaccharide (LPS) Challenge
Total cell count of neutrophils in Bronchoalveolar Lavage (BAL) fluid after 24 hours of the segmental Lipopolysaccharide (LPS) challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the Least Square (LS) means obtained by fitting an Analysis of variance (ANOVA) model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
Time frame: Day 29
Population: Pharmacodynamic set (PDS): The pharmacodynamic set included all treated subjects who had evaluable cell counts for the primary or secondary endpoints 24 h after segmental LPS challenge.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid After 24 Hours of the Segmental Lipopolysaccharide (LPS) Challenge | 687.02 cells*10^3/mililiter (mL) | Standard Error 109.315 |
| BI 1026706 | Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid After 24 Hours of the Segmental Lipopolysaccharide (LPS) Challenge | 872.61 cells*10^3/mililiter (mL) | Standard Error 145.019 |
Comparison: The statistical model used for the primary analysis of primary endpoints was an ANOVA model on the logarithmic scale. This model included the effect 'treatment'.p-value: 0.304390% CI: [0.86, 1.87]ANOVA
Secondary
Differential Cell Count of Eosinophil in BAL Fluid 24 h After Segmental LPS Challenge.
Differential cell count of eosinophil in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
Time frame: Day 29
Population: PDS
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Differential Cell Count of Eosinophil in BAL Fluid 24 h After Segmental LPS Challenge. | 0.55 Percentage of eosinophil | Standard Error 0.2 |
| BI 1026706 | Differential Cell Count of Eosinophil in BAL Fluid 24 h After Segmental LPS Challenge. | 0.65 Percentage of eosinophil | Standard Error 0.246 |
Comparison: The statistical model used for the analysis was an ANOVA model on the logarithmic scale. This model included the effect 'treatment'.90% CI: [0.49, 2.85]
Secondary
Differential Cell Count of Lymphocyte in BAL Fluid 24 h After Segmental LPS Challenge.
Differential cell count of lymphocyte in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
Time frame: Day 29
Population: PDS
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Differential Cell Count of Lymphocyte in BAL Fluid 24 h After Segmental LPS Challenge. | 1.67 Percentage of lymphocyte | Standard Error 0.283 |
| BI 1026706 | Differential Cell Count of Lymphocyte in BAL Fluid 24 h After Segmental LPS Challenge. | 1.07 Percentage of lymphocyte | Standard Error 0.19 |
Comparison: The statistical model used for the analysis was an ANOVA model on the logarithmic scale. This model included the effect 'treatment'.90% CI: [0.43, 0.97]
Secondary
Differential Cell Count of Macrophage+Monocyte in BAL Fluid 24 h After Segmental LPS Challenge.
Differential cell count of macrophage+monocyte in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Cytospin microscopy method cannot clearly differentiate between macrophages and monocytes, the total and differential cell count of macrophages and monocytes are presented together.
Time frame: Day 29
Population: PDS
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Differential Cell Count of Macrophage+Monocyte in BAL Fluid 24 h After Segmental LPS Challenge. | 39.03 Percentage of macrophage+monocyte | Standard Error 2.499 |
| BI 1026706 | Differential Cell Count of Macrophage+Monocyte in BAL Fluid 24 h After Segmental LPS Challenge. | 36.54 Percentage of macrophage+monocyte | Standard Error 2.444 |
Comparison: The statistical model used for the analysis was an ANOVA model on the logarithmic scale. This model included the effect 'treatment'.90% CI: [0.8, 1.09]
Secondary
Differential Cell Count of Monocyte in BAL Fluid 24 h After Segmental LPS Challenge.
Differential cell count of monocyte (determined by flow cytometry) in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Monocyte cell count is the only cell count which was assessed by means of flow cytometry.
Time frame: Day 29
Population: PDS
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Differential Cell Count of Monocyte in BAL Fluid 24 h After Segmental LPS Challenge. | 19.16 Percentage of monocyte | Standard Error 1.058 |
| BI 1026706 | Differential Cell Count of Monocyte in BAL Fluid 24 h After Segmental LPS Challenge. | 19.73 Percentage of monocyte | Standard Error 1.138 |
Comparison: The statistical model used for the analysis was an ANOVA model on the logarithmic scale. This model included the effect 'treatment'.90% CI: [0.9, 1.18]
Secondary
Differential Cell Count of Neutrophils in BAL Fluid 24 h After Segmental LPS Challenge.
Differential cell count of neutrophils in BAL fluid 24 h after segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
Time frame: Day 29
Population: PDS
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Differential Cell Count of Neutrophils in BAL Fluid 24 h After Segmental LPS Challenge. | 54.83 Percentage of neutrophils | Standard Error 3.094 |
| BI 1026706 | Differential Cell Count of Neutrophils in BAL Fluid 24 h After Segmental LPS Challenge. | 55.41 Percentage of neutrophils | Standard Error 3.266 |
Comparison: The statistical model used for the analysis was an ANOVA model on the logarithmic scale. This model included the effect 'treatment'.90% CI: [0.88, 1.16]
Secondary
Total Cell Count of Eosinophil in BAL Fluid After 24 Hours of the Segmental LPS Challenge
Total cell count of eosinophil in BAL fluid after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
Time frame: Day 29
Population: PDS
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Total Cell Count of Eosinophil in BAL Fluid After 24 Hours of the Segmental LPS Challenge | 6.95 cells*10^3/mL | Standard Error 2.744 |
| BI 1026706 | Total Cell Count of Eosinophil in BAL Fluid After 24 Hours of the Segmental LPS Challenge | 10.72 cells*10^3/mL | Standard Error 4.42 |
Comparison: The statistical model used for the primary analysis of primary endpoints was an ANOVA model on the logarithmic scale. This model included the effect 'treatment'.90% CI: [0.59, 4.03]
Secondary
Total Cell Count of Lymphocyte in BAL After 24 Hours of the Segmental LPS Challenge
Total cell count of lymphocyte after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method.
Time frame: Day 29
Population: PDS
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Total Cell Count of Lymphocyte in BAL After 24 Hours of the Segmental LPS Challenge | 20.99 cells*10^3/mL | Standard Error 3.976 |
| BI 1026706 | Total Cell Count of Lymphocyte in BAL After 24 Hours of the Segmental LPS Challenge | 16.91 cells*10^3/mL | Standard Error 3.346 |
Comparison: The statistical model used for the primary analysis of primary endpoints was an ANOVA model on the logarithmic scale. This model included the effect 'treatment'.90% CI: [0.51, 1.28]
Secondary
Total Cell Count of Macrophage+Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge
Total cell count of macrophage+monocyte BAL fluid after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Cytospin microscopy method cannot clearly differentiate between macrophages and monocytes, the total and differential cell count of macrophages and monocytes are presented together.
Time frame: Day 29
Population: PDS
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Total Cell Count of Macrophage+Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge | 488.95 cells*10^3/mL | Standard Error 52.417 |
| BI 1026706 | Total Cell Count of Macrophage+Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge | 575.43 cells*10^3/mL | Standard Error 64.431 |
Comparison: The statistical model used for the primary analysis of primary endpoints was an ANOVA model on the logarithmic scale. This model included the effect 'treatment'.90% CI: [0.91, 1.53]
Secondary
Total Cell Count of Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge
Total cell count of monocyte in BAL fluid after 24 hours of the segmental LPS challenge. The adjusted geometric means (gMeans) are obtained by exponentiating the LS means obtained by fitting an ANOVA model on the natural log transformed endpoint values, adjusted for treatment effect. Standard errors are derived using the delta method. Monocyte cell count is the only cell count which was assessed by means of flow cytometry.
Time frame: Day 29
Population: PDS
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Total Cell Count of Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge | 240.04 cells*10^3/mL | Standard Error 34.306 |
| BI 1026706 | Total Cell Count of Monocyte in BAL Fluid After 24 Hours of the Segmental LPS Challenge | 310.79 cells*10^3/mL | Standard Error 46.393 |
Comparison: The statistical model used for the primary analysis of primary endpoints was an ANOVA model on the logarithmic scale. This model included the effect 'treatment'.90% CI: [0.91, 1.83]